Pfizer to commercialise its IP with the help of trailblazing Roivant approach
The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
